ScholarLens Back to search
2007•Unpublished venueRequires access

LETTER TO THE EDITOR IMATINIB MESYLATE TREATMENT IN A PATIENT WITH CHEMORESISTANT Ph+ ACUTE MYELOID LEUKEMIA: POSSIBLE ROLE OF WILMS' TUMOR GENE 1

Eugenia Quartarone, Alessandro Allegra, Andrea Alonci, Giuseppe Toscano, Giacomo Bellomo, Elisabetta Corigliano, Vittorio Del Fabro, Caterina Musolino

Open publisher page 0 citations

Abstract

than 8 months 1 . Imatinib mesylate, an effective and selective inhibitor of BCR-ABL tyrosine kinase activity, is commonly used in the treatment of Ph-positive chronic myeloid leukemia (CML), also in the blastic phase, whereas its role in the treatment of Ph+ AML is not yet well understood. To our knowledge, few cases of Ph + AML have been treated with imatinib mesylate 2,3 .

About this research paper

What this paper is about

than 8 months 1 . Imatinib mesylate, an effective and selective inhibitor of BCR-ABL tyrosine kinase activity, is commonly used in the treatment of Ph-positive chronic myeloid leukemia (CML), also in the blastic phase, whereas its role in the treatment of Ph+ AML is not yet well understood. To our knowledge, few cases of Ph + AML have been treated with imatinib mesylate 2,3 .

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

than 8 months 1 . Imatinib mesylate, an effective and selective inhibitor of BCR-ABL tyrosine kinase activity, is commonly used in the treatment of Ph-positive chronic myeloid leukemia (CML), also in the blastic phase, whereas its role in the treatment of Ph+ AML is not yet well understood. To our knowledge, few cases of Ph + AML have been treated with imatinib mesylate 2,3 .

Key concepts: Imatinib mesylate, Myeloid leukemia, Medicine, Imatinib, Mesylate, Tyrosine kinase, Cancer research, Tyrosine-kinase inhibitor

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
LETTER TO THE EDITOR IMATINIB MESYLATE TREATMENT IN A PATIENT WITH CHEMORESISTANT Ph+ ACUTE MYELOID LEUKEMIA: POSSIBLE ROLE OF WILMS' TUMOR GENE 1 — Research Paper | ScholarLens